0.87  0 (0%)		12-31 19:00
Open: 0.906 High: 0.955 Volume: 941,412		Pre. Close: 0.87 Low: 0.8457 Market Cap: 0(M)

Short term
Mid term
Targets	6-month :	1.06	1-year :	1.11
Resists	First :	0.91	Second :	0.95
Pivot price	0.87
Supports	First :	0.84	Second :	0.7
MAs	MA(5) :	0.87	MA(20) :	0.87
	MA(100) :	0.87	MA(250) :	1.18
MACD	MACD :	0	Signal :	0
%K %D	K(14,3) :	22.2	D(3) :	22.2
RSI	RSI(14): 79.8
52-week	High :	3.42	Low :	0.1

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ ORPH ] has closed Bollinger Bands are 0% narrower than normal.

If tomorrow:	Open lower	Open higher
High:	0.96 - 0.96	0.96 - 0.97
Low:	0.83 - 0.84	0.84 - 0.84
Close:	0.86 - 0.87	0.87 - 0.88

Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company focuses on the amplification of heat-shock proteins to develop and commercialize therapeutics for diseases caused by protein misfolding and aggregation, and lysosomal dysfunction, including lysosomal storage and neuromuscular degenerative diseases. Its lead candidate is the Arimoclomol, which is in clinical development for four orphan diseases, including Niemann-Pick disease type C, Amyotrophic Lateral Sclerosis, Inclusion Body Myositis, and Gaucher disease. The company was incorporated in 2009 and is headquartered in Copenhagen, Denmark.

Wed, 22 Feb 2023
KemPharm rebrands to Zevra Therapeutics, doubling down on rare disease focus - MM+M Online

Fri, 11 Mar 2022
Orphazyme stock slumps 40% as it plans Nasdaq delisting, halve workforce in restructuring - Seeking Alpha

Wed, 01 Sep 2021
Forbion Appoints Nanna Lüneborg as a General Partner - Yahoo Finance

Mon, 12 Jul 2021
ORPHAZYME INVESTOR ALERT: Investors With Substantial Losses Have Opportunity to Lead the Orpahzyme A/S ... - Business Wire

Fri, 18 Jun 2021
Orphazyme’s Stocks Tumble After FDA Rejects Genetic Disease Drug Arimoclomol - BioSpace

Mon, 14 Jun 2021
Orphazyme Share Price, News: Brokerage Warns Over Latest Reddit Meme Stock - Bloomberg

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	0 (M)
Shares Float	35 (M)
Held by Insiders	2.815e+007 (%)
Held by Institutions	0 (%)
Shares Short	619 (K)
Shares Short P.Month	0 (K)

EPS	-7.6223e+008
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	-5 %
Return on Assets (ttm)	922.1 %
Return on Equity (ttm)	-88.2 %
Qtrly Rev. Growth	1.315e+007 %
Gross Profit (p.s.)	0
Sales Per Share	-335.12
EBITDA (p.s.)	0
Qtrly Earnings Growth	-3.9 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	-717 (M)

PE Ratio	-0.01
PEG Ratio	0
Price to Book value	0
Price to Sales	-0.01
Price to Cash Flow	0.13

Dividend	0
Forward Dividend	104770
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.